IL-6 receptor antagonists and antiplatelet agents improved chances for 6-month survival among patients with COVID-19, according to study results presented at Society of Critical Care Medicine’s ...

IL-6 triggers signal transduction after binding to the IL-6 receptor (IL-6R). [19,20] There are two forms of IL-6R, a transmembrane 80-kDa form with a short cytoplasmic domain and a soluble form ...

An IL-6 receptor inhibitor has already been developed. Now we need to use the findings from this study and others to better understand who will benefit the most from this new medication.

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune demyelinating disorder of the optic nerves and the spinal cord that is linked to the presence of anti-aquaporin (AQP4) autoantibodies.

One mechanism involves cis-signaling, where IL-6 interacts with its receptor on the cell surface, while the other involves trans-signaling, which uses a soluble form of IL-6 receptor.

In addition, Eleven could be entitled to receive royalties for net sales of potential future products containing EBI-031 or any other potential future products containing other Eleven IL-6 compounds.

Overall, use of IL-6 receptor antagonists (either tocilizumab or sarilumab) had a greater than 99.9% probability of improving 6-month survival, and use of antiplatelet agents (aspirin or a P2Y12 ...

The latter agents target the IL-6 receptor to prevent ligand binding and disrupt signalling from the receptor when already bound by IL-6. Olokizumab, on the other hand, binds directly to the IL-6 ...

Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. European Respiratory Review 19, 46-54 (2010). DOI: 10.1183/09059180.00007609 ...